Monday 14 June 2021 8:59 am | Updated: Friday 11 June 2021 2:45 pm

How tech and medical advances are transforming healthcare investing

Healthcare innovation specialist John Bowler explains the revolution going on in the sector.

Covid-19 aside, what other issues are emerging that will reshape the healthcare sector?

The main drivers of healthcare remain unchanged: there is accelerating demand for healthcare services as people are increasingly living longer. Governments around the world face budget pressures with the ever-growing demand for health services, this makes the need for more efficient health services a necessity and not an option.

Technology – the new insights in the biology of diseases and new treatment modalities – is also driving a tremendous wave of new medicines that offer a step change in patient outcomes. Just as exciting is the use of information age technology to make healthcare provision more efficient and improve quality.

What impact is technology having on the healthcare sector?

We are at the start of a transformational shift in knowledge and technology. The advancement of medical science in recent years has led to many new insights into disease biology which has driven a steady increase in innovative new medicines and associated diagnostics.

Medical technologies are contributing to novel therapeutic devices that are impacting a number of complex diseases, such has reducing the devastating impact of strokes. Digital health is already making healthcare provision more efficient and helping to drive better patient outcomes. It will serve to democratise the management of healthcare and well-being, providing individuals with the tools and data to take greater responsibility for their own personal health.

While these changes have been some time in the making, we are now at a positive inflection point where we will start to see genuine innovation and advancement across the sector. This will drive the returns of those companies at the forefront of innovation. This can be seen by a number of new, innovative drugs in areas such as oncology and gene therapy that are at the point of commercialisation. Meanwhile, the Covid-19 pandemic has accelerated the adoption of telehealth and digital services.

What are currently the most interesting sub-sectors in healthcare?

Sub-sectors most impacted by Covid-19 – hospitals, care providers and consumer healthcare (for example, hearing aids) are seeing a recovery in procedure/patient volume that is helping drive performance and we expect this will continue into next year. The rapid scale-up in Covid-19 vaccine production and the growing realisation that vaccinations will persist means there is still the potential for growth for companies involved in the production supply chain.

While sub-sectors such as biotech and healthcare technology have done well, there remain opportunities in the mid-term. There is a steady stream of exciting new biotech companies emerging from several geographies – these should benefit from either hitting key clinical trial milestones or as targets from acquisitive larger companies that need new products.

The lockdown period did shine a light on the value of telehealth and digital health services. This is being developed further into new tools to better manage chronic diseases such as diabetes using remote monitoring and artificial intelligence-enabled behavioural health products to improve outcomes. This trend is still relatively early in its adoption and therefore remains a source of mid- to long-term growth.

Are there any factors that could weaken growth in the future?

Budgetary pressure is going to become even more acute for governments, given how much has been borrowed so far. I think that creates an extra impetus for better management of resources. This requires fresh thinking and the adoption of technologies that benefit the patient, but it will also benefit healthcare systems in terms of cost.

Government policy towards healthcare, particularly regarding pricing, is always a consideration that grabs headlines, particularly linked to election cycles. The reality is that most governments need to incorporate private health services to augment and underpin varying levels of state healthcare provision. This means they need to create an environment that supports these companies.

What about sustainability?

There are three forces that we believe have the potential to make healthcare a sustainable growth area for many years to come. The first factor is demographics. Increasing numbers of older people around the world is driving an accelerating demand for healthcare services. In the US, for example, the oldest members of the so-called baby boomer generation are approaching 75, an age that sees peak utilisation of services such as hip replacements, hearing aids and other conditions of ageing.

The second factor is efficiency. The financial burden to national budgets and employer-sponsored health insurance is creating the necessary force for change. For example, in the US between 30% and 40% of healthcare spending is regarded as wasted, which creates a tremendous opportunity to drive efficiency.

The final critical factor is technology. There is a steady stream of novel and disruptive technologies in both medicines and technology/data that are providing new approaches to managing diseases. These are providing better patient outcomes in a more cost-effective manner.

The current Covid-19 crisis has just shone a large spotlight on the importance of these technologies. However, it’s the pace of rapid change across the sector that is now the most compelling reason for investors to consider the sector.

– For more visit Schroders insights and follow Schroders on twitter.

Topics:

Important Information: This communication is marketing material. The views and opinions contained herein are those of the author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds. This material is intended to be for information purposes only and is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. It is not intended to provide and should not be relied on for accounting, legal or tax advice, or investment recommendations. Reliance should not be placed on the views and information in this document when taking individual investment and/or strategic decisions. Past performance is not a reliable indicator of future results. The value of an investment can go down as well as up and is not guaranteed. All investments involve risks including the risk of possible loss of principal. Information herein is believed to be reliable but Schroders does not warrant its completeness or accuracy. Some information quoted was obtained from external sources we consider to be reliable. No responsibility can be accepted for errors of fact obtained from third parties, and this data may change with market conditions. This does not exclude any duty or liability that Schroders has to its customers under any regulatory system. Regions/ sectors shown for illustrative purposes only and should not be viewed as a recommendation to buy/sell. The opinions in this material include some forecasted views. We believe we are basing our expectations and beliefs on reasonable assumptions within the bounds of what we currently know. However, there is no guarantee than any forecasts or opinions will be realised. These views and opinions may change. To the extent that you are in North America, this content is issued by Schroder Investment Management North America Inc., an indirect wholly owned subsidiary of Schroders plc and SEC registered adviser providing asset management products and services to clients in the US and Canada. For all other users, this content is issued by Schroder Investment Management Limited, 1 London Wall Place, London EC2Y 5AU. Registered No. 1893220 England. Authorised and regulated by the Financial Conduct Authority.